Cellvation, Inc. is a clinical-stage biopharmaceutical company based in New York, NY, dedicated to developing innovative cellular therapeutics for the treatment of traumatic brain injury (TBI). With a focus on regenerative medicine, Cellvation aims to provide novel therapies that address the complex challenges associated with TBI.
As a subsidiary of Fortress Biotech, Cellvation is at the forefront of cutting-edge research and development in the field of TBI treatment. The company's pipeline includes promising candidates such as CEVA102 and CEVA-D, which have shown potential in clinical trials, offering hope for improved outcomes and quality of life for TBI patients.
Generated from the website